Progenics Pharmaceut (PGNX) 5.37 $PGNX
Progenics Pharmaceuticals (PGNX) Jumps: Stock Up 9.3%
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 7:15AM CDT
Progenics Pharmaceuticals, Inc. (PGNX) shares rose over 9% in the last trading session.
MNK: 62.52 (+0.23), PGNX: 5.37 (-0.10)
Progenics Pharmaceuticals, Inc. Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line and SUREtechnology Platform
BusinessWire - Tue Jun 21, 7:30AM CDT
Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, announced today that Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) has entered into a commercial license agreement for the use of Selexis' technology and proprietary CHO-K1 cell line.
PGNX: 5.37 (-0.10)
Commit To Purchase Progenics Pharmaceuticals At $4, Earn 20.7% Annualized Using Options
StockOptionsChannel.com - Mon Jun 20, 10:37AM CDT
Investors eyeing a purchase of Progenics Pharmaceuticals, Inc. stock, but cautious about paying the going market price of $4.77/share, might benefit from considering selling puts among the alternative strategies at their disposal.
PGNX: 5.37 (-0.10)
Biotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
PR Newswire - Tue Jun 14, 6:35AM CDT
On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial Average edged 0.74% lower, to finish at 17,732.48; and the S&P 500 closed at 2,079.06, down 0.81%. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Biogen Inc. (NASDAQ: BIIB), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and VIVUS Inc. (NASDAQ: VVUS). Learn more about these stocks by accessing their free trade alerts at:
PGNX: 5.37 (-0.10), BIIB: 252.54 (+1.24), VVUS: 1.14 (-0.04), PTCT: 7.47 (-0.06)
Progenics Pharmaceuticals Announces Presentations on its Prostate Cancer Imaging Programs at SNMMI 2016
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Progenics Pharmaceuticals, Inc. (NasdaqGNX) announced today that data from its 1404 and PyL prostate cancer imaging programs will be presented at the upcoming Society of Nuclear Medicine and Molecular Imaging 2016 Annual Meeting, taking place from June 11 - 15, 2016 in San Diego, California.
PGNX: 5.37 (-0.10)
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Progenics Pharmaceuticals, Inc. (NasdaqGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the election of Bradley Campbell to the Company's Board of Directors. Mr. Campbell brings to Progenics extensive experience in the biopharmaceutical industry, with particular expertise in the areas of corporate strategy, commercial operations and planning, business development and sales and marketing. He currently serves as President and Chief Operating Officer of Amicus Therapeutics, a biotechnology company focused on the development of therapies for a broad range of rare and orphan diseases.
PGNX: 5.37 (-0.10), FOLD: 5.91 (-0.09)
Progenics Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 7:30AM CDT
Progenics Pharmaceuticals, Inc., (NasdaqGNX), an oncology company focused on developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 11:30 a.m. Eastern Time. The conference is being held at the Grand Hyatt in New York, NY.
PGNX: 5.37 (-0.10)
Progenics reports 1Q loss
Automated Insights - Thu May 05, 8:48AM CDT
TARRYTOWN, N.Y. (AP) _ Progenics Pharmaceuticals Inc. (PGNX) on Thursday reported a loss of $12.7 million in its first quarter.
PGNX: 5.37 (-0.10)
Progenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results
GlobeNewswire - Thu May 05, 6:30AM CDT
-- On May 2nd, the Company Announced It Had Granted Exclusive World-Wide Rights to Bayer to Develop and Commercialize Products Using Progenics' PSMA Antibody Technology In Combination with Alpha-Emitting Radionuclides
PGNX: 5.37 (-0.10)
Progenics Licenses PSMA Antibody Technology to Bayer for Development of Alpha-Radiolabeled Therapeutic Antibodies
GlobeNewswire - Mon May 02, 7:30AM CDT
Progenics Pharmaceuticals, Inc. (NasdaqGNX) today announced that it has granted an exclusive license to Bayer for the development and commercialization of therapeutic antibodies combining the Company's prostate specific membrane antigen (PSMA) antibody technology with Bayer's targeted thorium conjugate technology.
PGNX: 5.37 (-0.10)
Progenics Pharmaceuticals Sets First Quarter 2016 Financial Results Call for May 5
GlobeNewswire - Thu Apr 21, 7:31AM CDT
Progenics Pharmaceuticals, Inc., (NasdaqGNX), an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review the first quarter ended March 31, 2016 financial results on Thursday, May 5, 2016, at 8:30 a.m. ET.
PGNX: 5.37 (-0.10)
Market Exclusive Research Weekly Biotech Report
ACCESSWIRE - Mon Apr 18, 8:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 18, 2016 / The week just gone gave us plenty to talk about in the biotech space, with two significant developments - one in oncology and one in a rare genetic growth disorder called acromegaly. Here's what happened, and how things played out as a result.
PGNX: 5.37 (-0.10), CLVS: 14.70 (-0.03), SRPT: 21.37 (-1.25), COLL: 12.63 (-0.11), CHMA: 2.82 (-0.16)
Progenics Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 4:00PM CDT
Progenics Pharmaceuticals, Inc. (NasdaqGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, CEO, is scheduled to present at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 8:40 a.m. Eastern Time. The conference is being held at The Westin Grand Central Hotel in New York, NY.
PGNX: 5.37 (-0.10)
Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR
PR Newswire - Mon Apr 04, 6:00AM CDT
Agency requests standard three-month extension to review additional solicited information-
PGNX: 5.37 (-0.10), VRX: 23.09 (-0.16), VRX.TO: 30.28 (-0.03)
Biotech Sector Report Analyst; Expecting FDA Results
ACCESSWIRE - Mon Mar 28, 7:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / MannKind Corporation (NASDAQ: MNKD), Keryx Biopharmaceuticals. (NASDAQ: KERX), Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), and BIND Therapeutics Inc. (NASDAQ: BIND) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
PGNX: 5.37 (-0.10), BIND: 0.53 (-0.03), MNKD: 1.14 (-0.03), KERX: 7.14 (-0.11)
Progenics Pharmaceuticals to Present at 28th Annual ROTH Conference
GlobeNewswire - Wed Mar 09, 4:00PM CST
Progenics Pharmaceuticals, Inc., (NasdaqGNX), an oncology company focused on developing innovative ways to target and treat cancer, announced today that Mark R. Baker, CEO, will present at the 28 Annual ROTH Conference in Dana Point, CA on Wednesday March 16, 2016 at 9:30 a.m. Pacific Time.
PGNX: 5.37 (-0.10)
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) Phase III Clinical Trial Expected; Analyst Report
ACCESSWIRE - Tue Feb 09, 8:05AM CST
CHICAGO, IL / ACCESSWIRE / February 9, 2016 / Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) an oncology company focused on developing innovative ways to target and treat cancer, recently announced that it has begun enrollment in its pivotal Phase 3 clinical trial evaluating 1404, a small molecule being developed as an imaging agent for prostate cancer. 1404 targets prostate specific membrane antigen (PSMA), which is abundantly expressed on prostate cancer cells. This Phase 3 clinical trial is expected to enroll approximately 450 patients with newly diagnosed low-grade prostate cancer who are candidates for active surveillance, but nonetheless are planning to undergo radical prostatectomy.
PGNX: 5.37 (-0.10)
Global Progenics Pharmaceuticals, Inc. Market Size, Share, Trend, Growth, Analysis and Forecast Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 7:59AM CST
'PROGENICS PHARMACEUTICALS, INC. - Product Pipeline Review - 2015', provides an overview of the PROGENICS PHARMACEUTICALS, INC.'s pharmaceutical research and development focus.
PGNX: 5.37 (-0.10)
Progenics Pharmaceuticals (PGNX) Jumps: Stock Up 9.3%
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 7:15AM CDT
Progenics Pharmaceuticals, Inc. (PGNX) shares rose over 9% in the last trading session.
MNK: 62.52 (+0.23), PGNX: 5.37 (-0.10)
Progenics Pharmaceuticals, Inc. Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line and SUREtechnology Platform
BusinessWire - Tue Jun 21, 7:30AM CDT
Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, announced today that Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) has entered into a commercial license agreement for the use of Selexis' technology and proprietary CHO-K1 cell line. PGNX: 5.37 (-0.10)
Commit To Purchase Progenics Pharmaceuticals At $4, Earn 20.7% Annualized Using Options
StockOptionsChannel.com - Mon Jun 20, 10:37AM CDT
Investors eyeing a purchase of Progenics Pharmaceuticals, Inc. stock, but cautious about paying the going market price of $4.77/share, might benefit from considering selling puts among the alternative strategies at their disposal.
PGNX: 5.37 (-0.10)
Biotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
PR Newswire - Tue Jun 14, 6:35AM CDT
On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial Average edged 0.74% lower, to finish at 17,732.48; and the S&P 500 closed at 2,079.06, down 0.81%. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Biogen Inc. (NASDAQ: BIIB), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and VIVUS Inc. (NASDAQ: VVUS). Learn more about these stocks by accessing their free trade alerts at:
PGNX: 5.37 (-0.10), BIIB: 252.54 (+1.24), VVUS: 1.14 (-0.04), PTCT: 7.47 (-0.06)
Progenics Pharmaceuticals Announces Presentations on its Prostate Cancer Imaging Programs at SNMMI 2016
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) announced today that data from its 1404 and PyL prostate cancer imaging programs will be presented at the upcoming Society of Nuclear Medicine and Molecular Imaging 2016 Annual Meeting, taking place from June 11 - 15, 2016 in San Diego, California. PGNX: 5.37 (-0.10)
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the election of Bradley Campbell to the Company's Board of Directors. Mr. Campbell brings to Progenics extensive experience in the biopharmaceutical industry, with particular expertise in the areas of corporate strategy, commercial operations and planning, business development and sales and marketing. He currently serves as President and Chief Operating Officer of Amicus Therapeutics, a biotechnology company focused on the development of therapies for a broad range of rare and orphan diseases. PGNX: 5.37 (-0.10), FOLD: 5.91 (-0.09)
Progenics Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 7:30AM CDT
Progenics Pharmaceuticals, Inc., (Nasdaq
GNX), an oncology company focused on developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 11:30 a.m. Eastern Time. The conference is being held at the Grand Hyatt in New York, NY. PGNX: 5.37 (-0.10)
Progenics reports 1Q loss
Automated Insights - Thu May 05, 8:48AM CDT
TARRYTOWN, N.Y. (AP) _ Progenics Pharmaceuticals Inc. (PGNX) on Thursday reported a loss of $12.7 million in its first quarter.
PGNX: 5.37 (-0.10)
Progenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results
GlobeNewswire - Thu May 05, 6:30AM CDT
-- On May 2nd, the Company Announced It Had Granted Exclusive World-Wide Rights to Bayer to Develop and Commercialize Products Using Progenics' PSMA Antibody Technology In Combination with Alpha-Emitting Radionuclides
PGNX: 5.37 (-0.10)
Progenics Licenses PSMA Antibody Technology to Bayer for Development of Alpha-Radiolabeled Therapeutic Antibodies
GlobeNewswire - Mon May 02, 7:30AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) today announced that it has granted an exclusive license to Bayer for the development and commercialization of therapeutic antibodies combining the Company's prostate specific membrane antigen (PSMA) antibody technology with Bayer's targeted thorium conjugate technology. PGNX: 5.37 (-0.10)
Progenics Pharmaceuticals Sets First Quarter 2016 Financial Results Call for May 5
GlobeNewswire - Thu Apr 21, 7:31AM CDT
Progenics Pharmaceuticals, Inc., (Nasdaq
GNX), an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review the first quarter ended March 31, 2016 financial results on Thursday, May 5, 2016, at 8:30 a.m. ET. PGNX: 5.37 (-0.10)
Market Exclusive Research Weekly Biotech Report
ACCESSWIRE - Mon Apr 18, 8:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 18, 2016 / The week just gone gave us plenty to talk about in the biotech space, with two significant developments - one in oncology and one in a rare genetic growth disorder called acromegaly. Here's what happened, and how things played out as a result.
PGNX: 5.37 (-0.10), CLVS: 14.70 (-0.03), SRPT: 21.37 (-1.25), COLL: 12.63 (-0.11), CHMA: 2.82 (-0.16)
Progenics Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 4:00PM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, CEO, is scheduled to present at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 8:40 a.m. Eastern Time. The conference is being held at The Westin Grand Central Hotel in New York, NY. PGNX: 5.37 (-0.10)
Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR
PR Newswire - Mon Apr 04, 6:00AM CDT
Agency requests standard three-month extension to review additional solicited information-
PGNX: 5.37 (-0.10), VRX: 23.09 (-0.16), VRX.TO: 30.28 (-0.03)
Biotech Sector Report Analyst; Expecting FDA Results
ACCESSWIRE - Mon Mar 28, 7:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / MannKind Corporation (NASDAQ: MNKD), Keryx Biopharmaceuticals. (NASDAQ: KERX), Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), and BIND Therapeutics Inc. (NASDAQ: BIND) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
PGNX: 5.37 (-0.10), BIND: 0.53 (-0.03), MNKD: 1.14 (-0.03), KERX: 7.14 (-0.11)
Progenics Pharmaceuticals to Present at 28th Annual ROTH Conference
GlobeNewswire - Wed Mar 09, 4:00PM CST
Progenics Pharmaceuticals, Inc., (Nasdaq
GNX), an oncology company focused on developing innovative ways to target and treat cancer, announced today that Mark R. Baker, CEO, will present at the 28 Annual ROTH Conference in Dana Point, CA on Wednesday March 16, 2016 at 9:30 a.m. Pacific Time. PGNX: 5.37 (-0.10)
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) Phase III Clinical Trial Expected; Analyst Report
ACCESSWIRE - Tue Feb 09, 8:05AM CST
CHICAGO, IL / ACCESSWIRE / February 9, 2016 / Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) an oncology company focused on developing innovative ways to target and treat cancer, recently announced that it has begun enrollment in its pivotal Phase 3 clinical trial evaluating 1404, a small molecule being developed as an imaging agent for prostate cancer. 1404 targets prostate specific membrane antigen (PSMA), which is abundantly expressed on prostate cancer cells. This Phase 3 clinical trial is expected to enroll approximately 450 patients with newly diagnosed low-grade prostate cancer who are candidates for active surveillance, but nonetheless are planning to undergo radical prostatectomy.
PGNX: 5.37 (-0.10)
Global Progenics Pharmaceuticals, Inc. Market Size, Share, Trend, Growth, Analysis and Forecast Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 7:59AM CST
'PROGENICS PHARMACEUTICALS, INC. - Product Pipeline Review - 2015', provides an overview of the PROGENICS PHARMACEUTICALS, INC.'s pharmaceutical research and development focus.
PGNX: 5.37 (-0.10)
